Product Description
Fluconazole is used to treat fungal infections, including yeast infections of the vagina, mouth, throat, esophagus (tube leading from the mouth to the stomach), abdomen (area between the chest and waist), lungs, blood, and other organs. Fluconazole is also used to treat meningitis (infection of the membranes covering the brain and spine) caused by fungus. Fluconazole is also used to prevent yeast infections in patients who are likely to become infected because they are being treated with chemotherapy or radiation therapy before a bone marrow transplant (replacement of unhealthy spongy tissue inside the bones with healthy tissue). Fluconazole is in a class of antifungals called triazoles. It works by slowing the growth of fungi that cause infection. (Sourced from: https://medlineplus.gov/druginfo/meds/a690002.html)
Mechanisms of Action: Cytochrome P450 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, Germany, Japan, South Africa, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 29
Highest Development Phases
Phase 3: COVID-19|Candidemia|Candidiasis, Invasive|Candidiasis, Oral|Candidiasis, Vulvovaginal|Crohn Disease|Influenza, Human
Phase 2: Hypercalciuria
Phase 1: Acute Pain|Bladder Cancer|Chronic Pain|Depressive Disorder|Healthy Volunteers|Low Back Pain|Lymphoma|Neuralgia|Oncology Unspecified|Pain, Postoperative|Respiratory Syncytial Virus Infections|Stroke|Urinary Calculi
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT06274554 | P3 |
Not yet recruiting |
Crohn Disease |
2028-12-01 |
|
| CIC-E-301 | P3 |
Not yet recruiting |
Influenza, Human|COVID-19 |
2025-03-15 |
39% |
| CIC-E-301 | P3 |
Not yet recruiting |
Influenza, Human|COVID-19 |
2025-03-15 |
39% |
| CIC-E-301 | P3 |
Not yet recruiting |
Influenza, Human|COVID-19 |
2025-03-15 |
39% |
| The FLUCOLITH study | P2 |
Active, not recruiting |
Hypercalciuria |
2024-05-14 |
|
| D7420C00003 | P1 |
Completed |
Healthy Volunteers |
2024-04-30 |
28% |
| D7420C00003 | P1 |
Completed |
Healthy Volunteers |
2024-04-30 |
28% |
| D7420C00003 | P1 |
Completed |
Healthy Volunteers |
2024-04-30 |
28% |